Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

Autor:	Laere, B, Rajan, P, Gronberg, H, Dirix, L, Lindberg, J, Mayrhofer, M, Whitington, T, van Dam, PJ, Van Oyen, P, Ghysel, C, Ampe, J, Ost, P, Demey, W, Hoela, L, Schrijvers, D, Brouwers, B, Lybaert, W, Everaert, E, De Maeseneer, D, Strijbos, M, Bols, A, Fransis, K, Beije, Nick, Kruijff, I (Ineke), Dam, V, Brouwer, A, Goossens, D, Heyrman, L, Van den Eynden, G, Rutten, A, Del Favero, J, Rantalainen, M, Sleijfer, Stefan, Ullen, A, Yachnin, J, van Laere, S, De Laere, L, Develter, T, Vantieghem, S, Herman, S, Coifs, G, Lamotte, V, Boumans, A, Baitar, A, Haeck, R, Wallays, G
Přispěvatelé:	Gastroenterology & Hepatology, Medical Oncology, CORE-ARV-CTC ProBIO Inves
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Wild type medicine.disease Androgen receptor Clinical trial 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine chemistry SDG 3 - Good Health and Well-being 030220 oncology & carcinogenesis Internal medicine Post-hoc analysis medicine Enzalutamide Human medicine 030212 general & internal medicine business Receptor Cohort study
Zdroj:	JAMA Oncology, 5(7), 1059-1061. American Medical Association JAMA ONCOLOGY
ISSN:	2374-2437
DOI:	10.1001/jamaoncol.2019.0869
Popis:	This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09b6f2104ba0f57f83c371eb07934c16 https://doi.org/10.1001/jamaoncol.2019.0869 Zobrazit plný text záznamu